The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Brain metabolite changes in cortical grey and normal-appearing white matter in clinically early relapsing-remitting multiple sclerosis
Abstract
While much work has concentrated on focal white matter (WM) lesions in multiple sclerosis, there is growing evidence to suggest that normal-appearing WM (NAWM) and grey matter (GM) are also involved in the disease process. This study investigated multiple sclerosis disease effects on NAWM and cortical GM (CGM) metabolite concentrations, and the relationships between these metabolite concentrations and clinical impairment. Proton magnetic resonance spectroscopic imaging ((1)H-MRSI) data acquired using point resolved spectroscopic (PRESS) localization (echo time 30 ms, repetition time 3000 ms, nominal voxel volume 2.3 ml) from 27 relapsing-remitting multiple sclerosis and 29 normal control (NC) subjects were processed using LCModel to estimate metabolite concentrations in millimoles per litre. (1)H-MRSI voxel tissue contents were estimated using SPM99 tissue and semi-automatic lesion segmentations of three-dimensional fast spoiled gradient recall scans acquired during the same scanning session. NAWM and CGM metabolite concentrations estimated were: choline-containing compounds (Cho); creatine and phosphocreatine (Cr); myo-inositol (Ins); N-acetyl-aspartate plus N-acetyl-aspartyl-glutamate (tNAA); and glutamate plus glutamine (Glx). CGM data came from 24 of the multiple sclerosis (mean age 35.2 years, mean disease duration 1.7 years) and 25 of the NC (mean age 34.9 years) subjects. NAWM data came from 25 of the multiple sclerosis (mean age 35.0 years, mean disease duration 1.7 years) and 28 of the NC (mean age 36.7 years) subjects. Metabolite concentrations were compared between multiple sclerosis and NC subjects using multiple (linear) regression models allowing for age, gender, (1)H-MRSI voxel tissue and CSF contents, and brain parenchymal volume. At a significance level of P < 0.05, CGM Cho, CGM and NAWM tNAA, and CGM Glx were all significantly reduced, and NAWM Ins was significantly elevated. Spearman correlations of multiple sclerosis functional composite scores with tissue metabolite concentrations were significant for the following: CGM Cr (r(s) = 0.524, P = 0.009), CGM Glx (r(s) = 0.580, P = 0.003) and NAWM Ins (r(s) = -0.559, P = 0.004). These results indicate that metabolite changes in NAWM and CGM can be detected early in the clinical course of multiple sclerosis, and that some of these changes relate to clinical status. The correlation of clinical impairment with CGM Cr and Glx but not tNAA suggests that it is more closely associated with neuronal metabolic dysfunction rather than loss in clinically early relapsing-remitting multiple sclerosis. The correlation of clinical impairment with a raised NAWM Ins may indicate that glial proliferation also relates to function at this stage of the disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)
Kurtzke, J. F. (1983) · Neurology · doi:10.1212/wnl.33.11.1444 · Cited by 15,011
Voxel-Based Morphometry—The Methods
Ashburner, J., & Friston, K. J. (2000) · NeuroImage · doi:10.1006/nimg.2000.0582 · Cited by 8,676
New diagnostic criteria for multiple sclerosis: Guidelines for research protocols
Poser, C. M., Paty, D. W., Scheinberg, L., McDonald, W. I., Davis, F. A., Ebers, G. C., Johnson, K. P., Sibley, W. A., Silberberg, D. H., & Tourtellotte, W. W. (1983) · Annals of Neurology · doi:10.1002/ana.410130302 · Cited by 7,384
Defining the clinical course of multiple sclerosis: Results of an international survey
Lublin, F. D., Reingold, S. C., & National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis* (1996) · Neurology · doi:10.1212/wnl.46.4.907 · Cited by 3,686
Estimation of metabolite concentrations from localized in vivo proton NMR spectra
Provencher, S. W. (1993) · Magnetic Resonance in Medicine · doi:10.1002/mrm.1910300604 · Cited by 3,655
Creatine and Creatinine Metabolism
Wyss, M., & Kaddurah-Daouk, R. (2000) · Physiological Reviews · doi:10.1152/physrev.2000.80.3.1107 · Cited by 2,950
Paced Auditory Serial-Addition Task: A Measure of Recovery from Concussion
Gronwall, D. M. A. (1977) · Perceptual and Motor Skills · doi:10.2466/pms.1977.44.2.367 · Cited by 2,395
Peterson, J. W., Bö, L., Mörk, S., Chang, A., & Trapp, B. D. (2001) · Annals of Neurology · doi:10.1002/ana.1123 · Cited by 1,403 · cited 2×
“, 2000), with neuronal involvement including axonal and dendritic transection, and neuronal apoptosis (Peterson et al., 2001).”
BackgroundDevelopment of a multiple sclerosis functional composite as a clinical trial outcome measure
Cutter, G. R. (1999) · Brain · doi:10.1093/brain/122.5.871 · Cited by 1,190
Multinuclear NMR Studies on the Energy Metabolism of Glial and Neuronal Cells
Brand, A., Richter-Landsberg, C., & Leibfritz, D. (1993) · Developmental Neuroscience · doi:10.1159/000111347 · Cited by 884
Cited by
Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis
Howell, O. W., Reeves, C. A., Nicholas, R., Carassiti, D., Radotra, B., Gentleman, S. M., Serafini, B., Aloisi, F., Roncaroli, F., Magliozzi, R., et al. (2011) · Brain · doi:10.1093/brain/awr182 · Cited by 858
Magnetization transfer ratio and myelin in postmortem multiple sclerosis brain
Schmierer, K., Scaravilli, F., Altmann, D. R., Barker, G. J., & Miller, D. H. (2004) · Annals of Neurology · doi:10.1002/ana.20202 · Cited by 776
Grey matter pathology in multiple sclerosis
Geurts, J. J., & Barkhof, F. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70191-1 · Cited by 507
Evidence of elevated glutamate in multiple sclerosis using magnetic resonance spectroscopy at 3 T
Srinivasan, R., Sailasuta, N., Hurd, R., Nelson, S., & Pelletier, D. (2005) · Brain · doi:10.1093/brain/awh467 · Cited by 465
Neocortical neuronal, synaptic, and glial loss in multiple sclerosis
Wegner, C., Esiri, M. M., Chance, S. A., Palace, J., & Matthews, P. M. (2006) · Neurology · doi:10.1212/01.wnl.0000237551.26858.39 · Cited by 441
Focal thinning of the cerebral cortex in multiple sclerosis
Sailer, M. (2003) · Brain · doi:10.1093/brain/awg175 · Cited by 398
Gray matter involvement in multiple sclerosis
Pirko, I., Lucchinetti, C. F., Sriram, S., & Bakshi, R. (2007) · Neurology · doi:10.1212/01.wnl.0000250267.85698.7a · Cited by 349
Evaluating and reducing the impact of white matter lesions on brain volume measurements
Battaglini, M., Jenkinson, M., & De Stefano, N. (2012) · Human Brain Mapping · doi:10.1002/hbm.21344 · Cited by 326
Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS
Malmeström, C., Haghighi, S., Rosengren, L., Andersen, O., & Lycke, J. (2003) · Neurology · doi:10.1212/01.wnl.0000098880.19793.b6 · Cited by 318
Calabrese, M., De Stefano, N., Atzori, M., Bernardi, V., Mattisi, I., Barachino, L., Morra, A., Rinaldi, L., Romualdi, C., Perini, P., et al. (2007) · Archives of Neurology · doi:10.1001/archneur.64.10.1416 · Cited by 309
MR Imaging of Multiple Sclerosis
Filippi, M., & Rocca, M. A. (2011) · Radiology · doi:10.1148/radiol.11101362 · Cited by 281
Smouldering multiple sclerosis: the ‘real MS’
Giovannoni, G., Popescu, V., Wuerfel, J., Hellwig, K., Iacobaeus, E., Jensen, M. B., García-Domínguez, J. M., Sousa, L., De Rossi, N., Hupperts, R., et al. (2022) · Therapeutic Advances in Neurological Disorders · doi:10.1177/17562864211066751 · Cited by 271
Cortical lesions in multiple sclerosis
Calabrese, M., Filippi, M., & Gallo, P. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.93 · Cited by 269
Brambilla, R. (2019) · Acta Neuropathologica · doi:10.1007/s00401-019-01980-7 · Cited by 246
Magnetic Resonance Spectroscopy Study of the Antioxidant Defense System in Schizophrenia
Matsuzawa, D., & Hashimoto, K. (2011) · Antioxidants & Redox Signaling · doi:10.1089/ars.2010.3453 · Cited by 79
Metabolites predict lesion formation and severity in relapsing-remitting multiple sclerosis
Klauser, A. M., Wiebenga, O. T., Eijlers, A. J., Schoonheim, M. M., Uitdehaag, B. M., Barkhof, F., Pouwels, P. J., & Geurts, J. J. (2018) · Multiple Sclerosis Journal · doi:10.1177/1352458517702534 · Cited by 28
Metadata
- Authors
- Chard, D. T.
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2002-10-01
- Volume
- 125
- Issue
- 10
- Pages
- 2342-2352
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W2106677794
- Cited by
- 280
- References
- 62
- FWCI
- 12.31
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.